Boston Research & Management’s Amgen AMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $435K | Hold |
1,237
| – | – | 0.1% | 86 |
|
|
2025
Q4 | $404K | Hold |
1,237
| – | – | 0.09% | 92 |
|
|
2025
Q3 | $349K | Hold |
1,237
| – | – | 0.08% | 100 |
|
|
2025
Q2 | $345K | Hold |
1,237
| – | – | 0.08% | 94 |
|
|
2025
Q1 | $385K | Hold |
1,237
| – | – | 0.1% | 93 |
|
|
2024
Q4 | $322K | Hold |
1,237
| – | – | 0.08% | 98 |
|
|
2024
Q3 | $398K | Hold |
1,237
| – | – | 0.09% | 96 |
|
|
2024
Q2 | $386K | Hold |
1,237
| – | – | 0.1% | 94 |
|
|
2024
Q1 | $351K | Hold |
1,237
| – | – | 0.09% | 100 |
|
|
2023
Q4 | $356K | Hold |
1,237
| – | – | 0.09% | 95 |
|
|
2023
Q3 | $332K | Hold |
1,237
| – | – | 0.1% | 94 |
|
|
2023
Q2 | $274K | Buy |
1,237
+50
| +4% | +$11.6K | 0.08% | 97 |
|
|
2023
Q1 | $286K | Hold |
1,187
| – | – | 0.09% | 97 |
|
|
2022
Q4 | $311K | Hold |
1,187
| – | – | 0.1% | 97 |
|
|
2022
Q3 | $267K | Hold |
1,187
| – | – | 0.09% | 97 |
|
|
2022
Q2 | $288K | Hold |
1,187
| – | – | 0.09% | 98 |
|
|
2022
Q1 | $287K | Hold |
1,187
| – | – | 0.08% | 98 |
|
|
2021
Q4 | $267K | Hold |
1,187
| – | – | 0.07% | 101 |
|
|
2021
Q3 | $252K | Hold |
1,187
| – | – | 0.08% | 100 |
|
|
2021
Q2 | $289K | Hold |
1,187
| – | – | 0.09% | 94 |
|
|
2021
Q1 | $295K | Buy |
1,187
+7
| +0.6% | +$1.67K | 0.1% | 91 |
|
|
2020
Q4 | $271K | Hold |
1,180
| – | – | 0.09% | 94 |
|
|
2020
Q3 | $299K | Hold |
1,180
| – | – | 0.12% | 87 |
|
|
2020
Q2 | $278K | Hold |
1,180
| – | – | 0.12% | 87 |
|
|
2020
Q1 | $239K | Hold |
1,180
| – | – | 0.12% | 84 |
|
|
2019
Q4 | $284K | Hold |
1,180
| – | – | 0.11% | 92 |
|
|
2019
Q3 | $228K | Hold |
1,180
| – | – | 0.09% | 94 |
|
|
2019
Q2 | $217K | Hold |
1,180
| – | – | 0.09% | 97 |
|
|
2019
Q1 | $224K | Hold |
1,180
| – | – | 0.09% | 98 |
|
|
2018
Q4 | $229K | Hold |
1,180
| – | – | 0.11% | 92 |
|
|
2018
Q3 | $244K | Sell |
1,180
-160
| -12% | -$31.5K | 0.11% | 91 |
|
|
2018
Q2 | $247K | Buy |
1,340
+160
| +14% | +$28.3K | 0.12% | 90 |
|
|
2018
Q1 | $201K | Hold |
1,180
| – | – | 0.1% | 95 |
|
|
2017
Q4 | $205K | Hold |
1,180
| – | – | 0.1% | 97 |
|
|
2017
Q3 | $220K | Hold |
1,180
| – | – | 0.11% | 93 |
|
|
2017
Q2 | $203K | Buy |
+1,180
| New | +$192K | 0.11% | 94 |
|
|
2015
Q1 | – | Sell |
-1,380
| Closed | -$219K | – | 101 |
|
|
2014
Q4 | $219K | Sell |
1,380
-300
| -18% | -$46.7K | 0.14% | 100 |
|
|
2014
Q3 | $235K | Buy |
+1,680
| New | +$219K | 0.16% | 93 |
|
|
2014
Q2 | – | Sell |
-1,680
| Closed | -$207K | – | 100 |
|
|
2014
Q1 | $207K | Buy |
+1,680
| New | +$204K | 0.15% | 98 |
|
Other funds holding AMGN
VCM
VPM
Boston Research & Management's AMGN Position: Q1 2026 in Review
Boston Research & Management held its Amgen (AMGN) position steady in Q1 2026 at 1,237 shares worth $435K. The position accounts for 0.1% of the portfolio, ranked #86.
Boston Research & Management first reported a position in AMGN in Q1 2014 and has held it in 39 quarters since. 3,126 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.
- Boston Research & Management held 1,237 shares of Amgen worth $435K as of Q1 2026.
- Boston Research & Management left its Amgen share count unchanged in Q1 2026.
- Amgen made up 0.1% of Boston Research & Management's portfolio in Q1 2026, its #86 holding.
- Boston Research & Management first reported a position in Amgen in Q1 2014 and has held it in 39 quarters since.
- 3,126 funds tracked by Wall St. Rank held Amgen as of Q1 2026.
Based on Boston Research & Management's 13F filing for Q1 2026, filed 10 Apr 2026.